# Pulmonology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Theodore Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI012-SYN
- Date: 2026-04-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Noor Haddad, MD
- Calendar frame: modern shifted

- Requested by: Amos Kettering, MD

## Reason for consultation

Lifelong asthma in a 23-year-old athlete, uncontrolled on albuterol alone. Please confirm the diagnosis and severity, assess for type 2 inflammation and allergic triggers, and advise on treatment step and exercise. **S**

## History

Mr. Roosevelt is seen at the request of Dr. Kettering four weeks after starting budesonide-formoterol maintenance-and-reliever therapy. He describes asthma since early childhood, quiet for some years in his teens and worse again over the past winter with colds. Since starting the new inhaler his symptoms have fallen to two or three days a week and night waking to once in four weeks. Colds and dusty rooms are his triggers. He has no nasal symptoms, reflux, snoring, stridor, or episodes of sudden throat tightness with normal breathing between. He believes that hard training is what keeps his asthma in check. **S**

## Examination

| System | Finding |
|---|---|
| General | Fit young man, talking easily |
| Nose | Normal mucosa; no polyps |
| Neck | No stridor at rest or on forced inspiration |
| Lungs | A few end-expiratory wheezes on forced expiration only |
| Inhaler technique | Did not breathe out before the dose and held his breath for only two seconds; corrected |

BP 116/70 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 72.4 kg; BMI 23.6 kg/m². All vital signs are synthetic.

## Data reviewed

Intake spirometry with bronchodilator response, the Asthma Control Test scores, and today's FeNO, blood eosinophil count, total IgE, and house dust mite specific IgE. Asthma Control Test: 18; FeNO: 46 [ppb] (high); Blood eosinophil count: 0.42 10*3/uL; Total IgE: 260 [IU]/mL (high); Dust mite (D. pteronyssinus) specific IgE: 8.4 k[IU]/L (high). All results are synthetic.

## Assessment

1. **Moderate persistent asthma** (J45.40). Confirmed: variable symptoms with reversible obstruction (17 percent and 540 mL bronchodilator response). Severity before treatment was moderate persistent by NAEPP impairment criteria (FEV1 72 percent predicted, night waking about twice a week). It is improving on Step 4 therapy, with an Asthma Control Test of 18. Nothing suggests vocal cord dysfunction. **S**
2. **Type 2 inflammation and allergic sensitization**. FeNO 46 ppb on inhaled corticosteroid, blood eosinophils 0.42 x10³/µL, and total IgE 260 IU/mL indicate type 2 inflammation. House dust mite specific IgE 8.4 kU/L shows sensitization that fits his symptoms in dusty rooms. **S**
3. **Exercise-related symptoms**. Mostly a sign of incomplete control, not a separate disorder. Exercise is good for him but does not treat the airway inflammation. **S**

## Recommendations

1. Continue budesonide-formoterol two inhalations twice daily and one as needed, up to 12 inhalations a day; the corrected technique and an evening-dose reminder should close most of the remaining gap.
2. Repeat spirometry three months after starting therapy.
3. Consider stepping down to one inhalation twice daily after at least three months of good control with no exacerbation.
4. One reliever inhalation 5 to 20 minutes before boxing or rowing, with a proper warm-up; keep training.
5. Dust-mite-impermeable mattress and pillow covers and weekly hot washing of bedding, since sensitization is documented.
6. Allergen immunotherapy is not needed while asthma is controlled; reconsider if dust-mite-related symptoms persist once control is stable. A biologic is not indicated, because the asthma is not severe.
7. PCV20 today for chronic lung disease, a yearly influenza vaccine, and a COVID-19 vaccine by CDC guidance.

## Strengths and supports

- Supports: close friends, a boxing coach, and colleagues at work **S**

## Communication

Discussed with Dr. Kettering the same day; the patient agrees with the plan and asked for a written summary for his training log. **S**

## Follow-up

Primary care will continue monitoring on the CMID schedule. Pulmonology will see him again for an exacerbation needing emergency care, two or more oral corticosteroid courses in a year while on treatment, or loss of control despite good adherence and technique. **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026), Aether Forge
- Summary of Risk-based Pneumococcal Vaccination Recommendations (2025), Centers for Disease Control and Prevention
